Navigation Links
Poniard Pharmaceuticals Announces Upcoming Conference Participation
Date:8/27/2008

SOUTH SAN FRANCISCO, Calif., Aug. 27 /PRNewswire-FirstCall/ -- Poniard Pharmaceuticals, Inc. (Nasdaq: PARD), a biopharmaceutical company focused on oncology, today announced that Jerry McMahon, Ph.D., chairman and CEO, will participate in three upcoming conferences in September during which he will provide a corporate overview, including a discussion of the clinical development program for picoplatin, the Company's lead product candidate.

-- The Thomas Weisel Partners Healthcare Conference on Wednesday, September 3, at 4:25 p.m. Eastern Time at the Four Seasons Hotel in Boston

-- BioCentury's NewsMakers in the Biotech Industry Conference on Thursday, September 4, at 2:30 p.m. Eastern Time at the Millennium Broadway Hotel in New York

-- The 3rd Annual Citi Biotech Day on Monday, September 8, at 2:35 p.m. Eastern Time at the Citi Center in New York

Live audio webcasts of Poniard's presentations at the Thomas Weisel Partners Healthcare Conference and Citi Biotech Day will be available for 10 business days following each conference. Each webcast can be accessed on the "Events" page of the "News & Events" section of the Company's website at http://www.poniard.com.

About Poniard Pharmaceuticals

Poniard Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of innovative oncology products to impact the lives of people with cancer. Picoplatin, the Company's lead platform product candidate, is a new generation platinum therapy with an improved safety profile relative to existing platinum-based cancer therapies. Picoplatin is designed to overcome platinum resistance associated with chemotherapy in solid tumors,
'/>"/>

SOURCE Poniard Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
2. Poniard Pharmaceuticals Announces Upgrade of Stock Listing to NASDAQ Global Market
3. Poniard Pharmaceuticals Announces European Commission Grants Orphan Medicinal Product Designation to Picoplatin for Treatment of Small Cell Lung Cancer
4. Poniard Pharmaceuticals Appoints Robert De Jager, M.D., as Chief Medical Officer
5. Poniard Pharmaceuticals Announces Upcoming Conference Participation
6. Poniard Pharmaceuticals Reports First Quarter 2008 Financial Results and Corporate Update
7. Poniard Pharmaceuticals Appoints Four New Members to Clinical Advisory Board
8. Poniard Pharmaceuticals to Host Second Quarter 2008 Financial Results Conference Call on July 31
9. Poniard Pharmaceuticals Announces Upcoming Conference Participation
10. Poniard Pharmaceuticals to Present at the 4th Annual Moores UCSD Cancer Center Translational Oncology Symposium
11. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... ARBOR, Mich. and LIBERTYVILLE, Ill. (PRWEB) , ... ... ... NSF International, a leading provider of regulatory compliance, quality systems, analytical ... Avarent LLC, a consulting firm with expertise in medical device products/processes development, ...
(Date:9/2/2015)... Florida (PRWEB) , ... September 02, 2015 , ... ... been treated and managed with the use of special anti-vascular endothelial growth factor ... in many more patients, currently does not have a scientific protocol for the ...
(Date:9/2/2015)... DUBLIN , Sep. 02, 2015 /PRNewswire/ ... ( http://www.researchandmarkets.com/research/bvxxkf/cytogenetics ) has announced the addition ... - Technologies, Markets and Companies" to ... cytogenetics includes several technologies besides fluorescence in ... and multicolor FISH. Molecular cytogenetics includes application ...
(Date:9/2/2015)... 2, 2015  Neurotech Pharmaceuticals, Inc., announced today ... multicenter Phase 2 clinical trial of NT-503 Encapsulated ... recurrent subfoveal choroidal neovascularization secondary to age related ... vascular endothelial growth factor (VEGF) receptor protein continuously ... "This landmark proof-of-concept study will evaluate NT-503 ECT ...
Breaking Biology Technology:NSF International Strengthens Medical Device Consulting With Acquisition of Avarent LLC 2NSF International Strengthens Medical Device Consulting With Acquisition of Avarent LLC 3NSF International Strengthens Medical Device Consulting With Acquisition of Avarent LLC 4NSF International Strengthens Medical Device Consulting With Acquisition of Avarent LLC 5NSF International Strengthens Medical Device Consulting With Acquisition of Avarent LLC 6NSF International Strengthens Medical Device Consulting With Acquisition of Avarent LLC 7StemCell GeneticMed Announces That It Has Started Stem Cell Treatments for Age Related Dry Macular Degeneration (AMG) 2Global Cytogenetics Technologies Study 2015-2025 - Latest Markets and Companies Analysis 2Global Cytogenetics Technologies Study 2015-2025 - Latest Markets and Companies Analysis 3Neurotech Announces First Patient Enrolled in Novel Anti-VEGF Encapsulated Cell Therapy Study 2Neurotech Announces First Patient Enrolled in Novel Anti-VEGF Encapsulated Cell Therapy Study 3Neurotech Announces First Patient Enrolled in Novel Anti-VEGF Encapsulated Cell Therapy Study 4
... Rudy Willebrords 1 and Bart Moyson 2 ... Johnson & Johnson Pharmaceutical Research & Development, a division of Janssen Pharmaceutica N.V., ... 2 Caliper Life Sciences Benelux NV, Teralfene, Belgium , ... The purpose of this paper is to report the ...
... and Brent Butler 2 , ... USA , ... Introduction , ... out using manual pipetting. As the demand for greater throughput of plate processing ...
... Jeff Cunningham and Lynn Jordan , ... Laboratory, Hopkinton, Massachusetts, USA , ... The ability to continuously dispense reagents across multi-well plates and into ... laboratories. Equally important, however, is the precision that can be achieved ...
Cached Biology Technology:96 Well Pipetting Precision Testing Using the Sciclone ALH with a 384 Fixed-Cannula Array 296 Well Pipetting Precision Testing Using the Sciclone ALH with a 384 Fixed-Cannula Array 396 Well Pipetting Precision and Accuracy Using the RapidPlate 96/384 Workstation 296 Well Pipetting Precision and Accuracy Using the RapidPlate 96/384 Workstation 396 Well Pipetting Precision and Accuracy Using the RapidPlate 96/384 Workstation 4Sciclone ALH Bulk Dispense Precision Testing 2
(Date:8/25/2015)... CITY and BELLEVUE, Wash. ... leader in advanced robotic systems, announced today it will ... unmanned ground vehicle (UGV), at the National Tactical Officers ... The Guardian S is the first-ever ... culmination of years of research and in-field trials and ...
(Date:8/20/2015)... CLARA, Calif. , Aug. 20, 2015 /PRNewswire/ ... company focused on improving the user experience and ... and vision technologies, today announced that its ... voice biometric authentication software to be FIDO ... tested TrulySecure for compliance with the FIDO UAF ...
(Date:8/18/2015)... Research and Markets ( http://www.researchandmarkets.com/research/9dmm6l/global_biometric ) ... Biometric Authentication & Identification Market: Focus On Modality, ... report to their offering. ... is expected to grow at an estimated CAGR ... over $25 billion (approximately) by 2020 as per ...
Breaking Biology News(10 mins):Sarcos to Debut First-of-its-Kind Snake Robot 2Sarcos to Debut First-of-its-Kind Snake Robot 3TrulySecure From Sensory Becomes First Face and Voice Biometrics Technology to be FIDO UAF Certified 2TrulySecure From Sensory Becomes First Face and Voice Biometrics Technology to be FIDO UAF Certified 3TrulySecure From Sensory Becomes First Face and Voice Biometrics Technology to be FIDO UAF Certified 4TrulySecure From Sensory Becomes First Face and Voice Biometrics Technology to be FIDO UAF Certified 5Global Biometric Authentication & Identification Market 2015: Focus On Modality, Motility & Application - Estimation & Forecasts to 2020 for the $25 Billion Industry 2
... An effort in King County, Washington, to add nutrition facts ... behavior in its first year. As part of ... county, which includes Seattle and environs, imposed a mandatory menu ... locations beginning in January, 2009. Restaurants had to disclose calorie ...
... States and Ecuador has pinpointed 1898 as the year the ... infecting its birds. This estimation is vital to understanding avian ... on the subject, "110 Years of Avipoxvirus on the Galapagos ... ONE , an international, open-access science publication. , The research ...
... the Duke Cancer Institute who have been studying prostate cancer ... antigen) levels reflect cancer progression. "This is the first ... bad thing for a tumor to produce," said senior author ... Pathology. "I am willing to bet there is also a ...
Cached Biology News:Mandatory menu labeling didn't change behavior at 1 fast food chain 2100-year-old specimens at California museum help determine when avian pox hit Galapagos 2100-year-old specimens at California museum help determine when avian pox hit Galapagos 3Researchers learn why PSA levels reflect prostate cancer progression 2Researchers learn why PSA levels reflect prostate cancer progression 3
The stirbar is used in the buffer tank of the Trans-Blot Plus cell to maintain uniform conductivity and temperature during electrophoretic transfer. Dimensions are 3.5 x 0.5 in....
... latest entry in the Biomek line. With an,up-to-date ... robustness, it can meet the needs of just ... either one or two pipetting pods. With its ... standard for flexible laboratory solutions to meet your ...
... The Biomek FX P is the ... hardware design for greater positional accuracy and increased ... about any application. It can be configured with ... large deck capacity, the Biomek FX P ...
... and you reduce the chance of error. ... 8000. Developed using Beckman Coulters extensive experience ... electrophoresis technology, the CEQ 8000 is a ... automatically fills the capillary array with a ...
Biology Products: